[1] EMERY M A, AKIL H. Endogenous opioids at the intersection of opioid addiction, pain, and depression: the search for a precision medicine approach[J]. Annu Rev Neurosci, 2020, 43:355-374.
[2] PARK K, OTTE A. Prevention of opioid abuse and treatment of opioid addiction: current status and future possibilities[J]. Annu Rev Biomed Eng, 2019, 21:61-84.
[3] COMPTON W M, VALENTINO R J, DUPONT R L. Polysubstance use in the U.S. opioid crisis[J]. Mol Psychiatry, 2021, 26(1):41-50.
[4] TANG J, LEE T, SUN T. Single-nucleotide editing: from principle, optimization to application[J]. Hum Mutat, 2019, 40(12):2171-2183.
[5] MANGLIK A. Molecular basis of opioid action: from structures to new leads[J]. Biol Psychiatry, 2020, 87(1):6-14.
[6] ABI A, SAFAVI A. Targeted detection of single-nucleotide variations: progress and promise[J]. ACS Sens, 2019, 4(4):792-807.
[7] CHAMOUN E, MUTCH D M, ALLEN-VERCOE E, et al.A review of the associations between single nucleotide polymorphisms in taste receptors, eating behaviors, and health[J]. Crit Rev Food Sci Nutr, 2018, 58(2):194-207.
[8] RABINOWITZ R, OFFEN D. Single-base resolution: increasing the specificity of the CRISPR-Cas system in gene editing[J]. Mol Ther, 2021, 29(3):937-948.
[9] SCHÜRCH A C, ARREDONDO-ALONSO S, WILLEMS R, et al. Whole genome sequencing options for bacterial strain typing and epidemiologic analysis based on single nucleotide polymorphism versus gene-by-gene-based approaches[J]. Clin Microbiol Infect, 2018, 24(4):350-354.
[10] WOOLF C J. Capturing novel non-opioid pain targets[J]. Biol Psychiatry, 2020, 87(1):74-81.
[11] AHMAD T, VALENTOVIC M A, RANKIN G O. Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics[J]. Biochem Pharmacol, 2018, 153:196-204.
[12] AZZAM A, MCDONALD J, LAMBERT D. Hot topics in opioid pharmacology: mixed and biased opioids[J]. Br J Anaesth, 2019, 122(6):e136-e145.
[13] SRIVASTAVA A, MARIANI J, LEVIN F. New directions in the treatment of opioid withdrawal[J]. Lancet, 2020, 395(10241):1938-1948.
[14] GILLIS A, KLIEWER A, KELLY E et al. Critical assessment of G protein-biased agonism at the μ-opioid receptor[J]. Trends Pharmacol Sci, 2020, 41(12):947-959.
[15] OFOEGBU A, ETTIENNE E. Pharmacogenomics and morphine[J]. J Clin Pharmacol, 2021, 61(9):1149-1155.
[16] WANG W, ZHOU Q, YUAN C. Influence of (ATP)-binding cassette transporter subfamily B member 1 (ABCB1) gene polymorphism on the efficacy of remifentanil[J]. Med Sci Monit, 2019, 25:5258-5262.
[17] IWERSEN-BERGMANN S, PLATTNER S, HISCHKE S, et al. Brain/blood ratios of methadone and ABCB1 polymorphisms in methadone-related deaths[J]. Int J Legal Med, 2021, 135(2):473-482.
[18] LUO R, LI X, QIN S, et al. Impact of SNP-SNP interaction among ABCB1, ARRB2, DRD1 and OPRD1 on methadone dosage requirement in Han Chinese patients[J]. Pharmacogenomics, 2017, 18(18):1659-1670.
[19] YANG G, BARNES N M, LYON D E, et al. Genetic variants associated with cancer pain and response to opioid analgesics: implications for precision pain management[J]. Semin Oncol Nurs, 2019, 35(3):291-299.
[20] HOOTEN W, HU D, JULIE M. Effects of the ABCB1 c.3435C>T (rs1045642) polymorphism on heat pain perception in opioid-free adults with chronic pain[J]. Anesth Analg, 2021, 133(4):1028-1035.
[21] BENAVIDES R, VSEVOLOZHSKAYA O, CATTANEO S, et al. A functional polymorphism in the ATP-Binding Cassette B1 Transporter predicts pharmacologic response to combination of nortriptyline and morphine in neuropathic pain patients[J]. Pain, 2020, 161(3):619-629.
[22] SMITH D, WEITZEL K, ELSEY A, et al. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial[J]. Genet Med, 2019, 21(8):1842-1850.
[23] SAIZ-RODRÍGUEZ M, OCHOA D, ROMÁN M, et al. Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics[J]. Pharmacogenomics, 2020, 21(10):663-675.
[24] REIZINE N, DANAHEY K, SCHIERER E, et al.Impact of CYP2D6 pharmacogenomic status on pain control among opioid-treated oncology patients[J]. Oncologist, 2021, 26(11):e2042-e2052.
[25] STORELLI F, MATTHEY A, LENGLET S, et al. Impact of CYP2D6 functional allelic variations on phenoconversion and drug-drug interactions[J]. Clin Pharmacol Ther, 2018, 104(1):148-157.
[26] ARAFA M, ATTEIA H. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6) are associated with long term tramadol treatment-induced oxidative damage and hepatotoxicity[J] .Toxicol Appl Pharmacol, 2018, 346:37-44.
[27] LV J, LIU F, FENG N, et al.CYP3A4 gene polymorphism is correlated with individual consumption of sufentanil[J]. Acta Anaesthesiol Scand, 2018, 62(10):1367-1373.
[28] ZHANG J L, ZHANG L, ZHAO X, et al.Association between MDR/CYP3A4/OPRM gene polymorphisms and the post-caesarean fentanyl analgesic effect on Chinese women[J]. Gene, 2018, 661:78-84.
[29] MURRONE A, BOROTTO G, FAVRETTO D, et al. Opioid resistance associated with CYP3A4 hyperactivity and COMT polymorphism in an oncological patient[J]. Pain Med, 2018, 19(3):638-640.
[30] ROBINSON S, JONES A, BRYNILDSEN J, et al. Neurobehavioral effects of neonatal opioid exposure in mice: influence of the OPRM1 SNP[J] .Addict Biol, 2020, 25(5):806-814.
[31] TOLAMI H, SHARAFSHAH A, TOLAMI L, et al. Haplotype-based association and in silico studies of OPRM1 gene variants with susceptibility to opioid dependence among addicted Iranians undergoing methadone treatment[J]. J Mol Neurosci, 2020, 70(4):504-513.
[32] SAIZ-RODRÍGUEZ M, OCHOA D, HERRADOR C, et al. Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects[J]. Basic Clin Pharmacol Toxicol, 2019, 124(3):321-329.
[33] NARAYAN A, HUNKELE A, XU J, et al. Mu opioids induce biased signaling at the full-length seven transmembrane C-terminal splice variants of the mu opioid receptor gene, Oprm1[J]. Cell Mol Neurobiol, 2021, 41(5):1059-1074.
[34] TCHALOVA K, SADIKAJ G, MOSKOWITZ D S, et al. Variation in the μ-opioid receptor gene (OPRM1) and experiences of felt security in response to a romantic partner's quarrelsome behavior[J]. Mol Psychiatry, 2021, 26(8):3847-3857.
[35] NASCIMENTO T D, YANG N, SALMAN D, et al. μ-opioid activity in chronic TMD pain is associated with COMT polymorphism[J]. J Dent Res, 2019, 98(12):1324-1331.
[36] HU B, ZHANG X, XU G, et al.Association between COMT polymorphism Val158Met and opioid consumption in patients with postoperative pain: a meta-analysis[J]. Neurosignals, 2018, 26(1):11-21.
[37] BARTOSOVA O, SIMA M, POLANECKY O, et al. Analgesic effects of piritramide in acute postoperative pain - comparison of intramuscular administration with patient-controlled intravenous analgesia and impact of OPRM1 and ABCB1 polymorphisms[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2022, 166(1):40-45.
[38] KNISELY M, CARPENTER J, DRAUCKER C, et al. CYP2D6 drug-gene and drug-drug-gene interactions among patients prescribed pharmacogenetically actionable opioids[J]. Appl Nurs Res, 2017, 38:107-110.
[39] CREWS K, MONTE A, HUDDART R, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy[J]. Clin Pharmacol Ther, 2021, 110(4):888-896. |
